High-throughput Drug Perturbation in Patient-Derived Gliomaspheres Enables Patient Stratification

• Value of deep genetic characterisation and functional genomics on low-passage patient-derived glioma tumorspheres
• Genetic biomarker identification and validation
• Rapid clinical impact of tumour precision targeting by clinical stage drugs

Speakers:

Liisi Laaniste

Chief Scientific Officer and Co-Founder

CoSyne Therapeutics